Pan-cancer analysis of whole genomes reveals driver rearrangements promoted by LINE-1 retrotransposition in human tumours

Bernardo Rodríguez–Martín, Eva G. Álvarez, Adrian Baez‐Ortega, Jorge Zamora, Fran Supek, Jonas Demeulemeester, Martín Santamarina, Young Seok Ju, Javier Temes, Daniel García‐Souto, Harald Detering, Yilong Li, Jorge Rodríguez‐Castro, Ana Dueso-Barroso, Alicia L. Bruzos, Stefan C. Dentro, Miguel G. Blanco, Gianmarco Contino, Daniel Ardeljan, Marta Tojo, Nicola D. Roberts, Sonia Zumalave, Paul A. Edwards, Joachim Weischenfeldt, Montserrat Puiggròs, Zechen Chong, Ken Chen, Eunjung Alice Lee, Jeremiah A. Wala, Keiran Raine, Adam P. Butler, Sebastian M. Waszak, Fábio C. P. Navarro, Steven E. Schumacher, Jean Monlong, Francesco Maura, Niccolò Bolli, Guillaume Bourque, Mark Gerstein, Peter J. Park, David C. Wedge, Rameen Beroukhim, David Torrents, Jan O. Korbel, Iñigo Martincorena, Rebecca C. Fitzgerald, Peter Van Loo, Haig H. Kazazian, Kathleen H. Burns, Peter J. Campbell, José M. C. Tubío, on behalf of the Pcawg Structural Variation Working Group, the Icgc/tcga Pan-Cancer Analysis of Whole Genomes NetworkbioRxiv 2017 · DOI

TL;DR

This study reveals that LINE-1 (L1) retrotransposons, often considered "junk DNA," are active drivers of genomic rearrangements in nearly half of all cancers. By analyzing thousands of tumor genomes, researchers found that L1 activity can lead to large-scale deletions, translocations, and gene amplifications, significantly contributing to cancer development and evolution.

What Problem Does This Paper Address?

For a long time, repetitive elements like LINE-1 (L1) retrotransposons in our genome were largely dismissed as inactive "junk DNA." However, there's been growing suspicion that these elements might play a role in disease, particularly cancer. The challenge has been to systematically identify and characterize the activity of these mobile elements within the complex landscape of cancer genomes. Specifically, researchers wanted to understand:

  • How common are somatic (acquired during a person's lifetime) L1 retrotransposition events in cancer?
  • What are the specific mechanisms by which L1s cause genomic changes?
  • Do these L1-driven changes contribute to cancer development or progression?

This paper aims to address these questions by providing a comprehensive, pan-cancer analysis of L1 retrotransposition.

Methods

The researchers employed a multi-faceted approach:

  • Bioinformatic Pipeline (TraFiC-mem): They developed and utilized a novel computational pipeline called TraFiC-mem to identify somatic mobile element insertions (MEIs), including L1s, across thousands of whole-genome sequences. This pipeline was validated using both in-silico simulations and single-molecule sequencing data.
  • Whole-Genome Sequencing (WGS): They analyzed WGS data from 2,954 tumor samples across 37 cancer subtypes.
  • RNA-sequencing (RNA-seq): This was used to investigate the transcriptional impact of L1 insertions on gene expression.
  • Copy Number Analysis: This helped identify large-scale deletions and amplifications.
  • Structural Variant (SV) Analysis: This provided a broader view of genomic rearrangements.
  • Statistical Modeling: They used negative binomial regression and Mann-Whitney U tests to associate L1 activity with genomic features and TP53 mutations.

Datasets

  • Pan-Cancer Analysis of Whole Genomes (PCAWG) Project: The primary dataset comprised whole-genome sequencing data from 2,954 tumor samples and their matched normal pairs, representing 37 histological cancer subtypes.
  • RNA-sequencing data: Available for about half of the PCAWG donors.
  • Cancer Gene Census (COSMIC) database: Used for annotating MEIs within cancer genes.

Key Insights and Ideas

  • L1s are surprisingly active in cancer: Contrary to the idea of L1s being mostly dormant, this study shows they are actively involved in shaping cancer genomes.
  • L1s are major drivers of structural variation: L1 insertions are not just passive passengers; they actively cause significant genomic alterations, including deletions and translocations.
  • "Junk DNA" can be oncogenic: The study highlights how elements once considered non-functional can directly contribute to cancer development by disrupting tumor suppressor genes or amplifying oncogenes.
  • Distinct L1 activity patterns: The researchers identified two patterns of "hot-L1" activity, termed "Strombolian" and "Plinian," based on their frequency and intensity of retrotransposition.

Key Results

  • Prevalence: Approximately 50% of human tumors exhibit somatic retrotransposition of L1 elements.
  • Event Count: 19,166 somatically acquired retrotransposition events were identified across 35% of samples.
  • Structural Variation: L1 insertions are the most frequent type of somatic structural variation in esophageal adenocarcinoma and the second most frequent in head-and-neck and colorectal cancers.
  • Genomic Impact: Aberrant L1 integrations can cause:
  • Megabase-scale deletions: Removing tumor suppressor genes (e.g., CDKN2A).
  • Complex translocations and large-scale duplications.
    • Breakage-fusion-bridge cycles: Leading to high-level amplification of oncogenes (e.g., CCND1).
  • Cancer Type Enrichment: Esophageal adenocarcinoma, head-and-neck squamous carcinoma, lung squamous carcinoma, and colorectal adenocarcinoma showed significantly higher rates of somatic retrotranspositions.
  • TP53 Association: Tumors with TP53 mutations exhibited increased L1 retrotransposition rates, suggesting TP53 may normally restrain mobile elements.

Limitations and Future Work

  • Fragment Size Constraints: The authors acknowledge that fragment size limitations of paired-end sequencing libraries might have led to an underestimation of the frequency of structural variants induced by somatic retrotransposition.
  • Long-Read Sequencing: They suggest that long-read sequencing technologies could provide a more complete picture of the frequency of these events.
  • Functional Consequences: While the study identifies L1-mediated rearrangements and their potential to disrupt genes, further functional studies would be needed to fully elucidate their precise impact on cancer progression.
  • Therapeutic Implications: The findings suggest that targeting L1 activity or its consequences could be a potential avenue for cancer therapy, though this is not explicitly detailed as future work in the paper.

Summary updated

Abstract

Abstract About half of all cancers have somatic integrations of retrotransposons. To characterize their role in oncogenesis, we analyzed the patterns and mechanisms of somatic retrotransposition in 2,954 cancer genomes from 37 histological cancer subtypes. We identified 19,166 somatically acquired retrotransposition events, affecting 35% of samples, and spanning a range of event types. L1 insertions emerged as the first most frequent type of somatic structural variation in esophageal adenocarcinoma, and the second most frequent in head-and-neck and colorectal cancers. Aberrant L1 integrations can delete megabase-scale regions of a chromosome, sometimes removing tumour suppressor genes, as well as inducing complex translocations and large-scale duplications. Somatic retrotranspositions can also initiate breakage-fusion-bridge cycles, leading to high-level amplification of oncogenes. These observations illuminate a relevant role of L1 retrotransposition in remodeling the cancer genome, with potential implications in the development of human tumours.
BibTeX
@misc{rodriguezmartin2017pan,
  author = {Bernardo Rodríguez–Martín and Eva G. Álvarez and Adrian Baez‐Ortega and Jorge Zamora and Fran Supek and Jonas Demeulemeester and Martín Santamarina and Young Seok Ju and Javier Temes and Daniel García‐Souto and Harald Detering and Yilong Li and Jorge Rodríguez‐Castro and Ana Dueso-Barroso and Alicia L. Bruzos and Stefan C. Dentro and Miguel G. Blanco and Gianmarco Contino and Daniel Ardeljan and Marta Tojo and Nicola D. Roberts and Sonia Zumalave and Paul A. Edwards and Joachim Weischenfeldt and Montserrat Puiggròs and Zechen Chong and Ken Chen and Eunjung Alice Lee and Jeremiah A. Wala and Keiran Raine and Adam P. Butler and Sebastian M. Waszak and Fábio C. P. Navarro and Steven E. Schumacher and Jean Monlong and Francesco Maura and Niccolò Bolli and Guillaume Bourque and Mark Gerstein and Peter J. Park and David C. Wedge and Rameen Beroukhim and David Torrents and Jan O. Korbel and Iñigo Martincorena and Rebecca C. Fitzgerald and Peter Van Loo and Haig H. Kazazian and Kathleen H. Burns and Peter J. Campbell and José M. C. Tubío and on behalf of the PCAWG Structural Variation Working Group and the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Network},
  title = {{Pan-cancer analysis of whole genomes reveals driver rearrangements promoted by LINE-1 retrotransposition in human tumours}},
  year = {2017},
  doi = {10.1101/179705},
  howpublished = {bioRxiv},
}
Figure